You are here: Industry Insights > nivolumab

News List

Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combinati pharmaceutical-business-review
May 08, 2020
Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology.
FDA Grants Accelerated Approval to Nivolumab, Ipilimumab Combination americanpharmaceuticalreview
March 18, 2020
The Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.) ...
NICE asks BMS for more data before approving cancer drug europeanpharmaceuticalreview
May 08, 2019
NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma…
How are the First Lung Cancer Patients Treated with Opdivo 4.5 Years Later? PharmaSources/Yefenghong
April 29, 2019
Since Opdivo was approved, it has started its unbelievable road, and has so far been approved 17 indications by the FDA.
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma worldpharmanews
January 17, 2019
This decision represents the first approval of an Immuno-Oncology (I-O) combination therapy for patients with this type of cancer in the European Union.
NICE turns down Opdivo/Yervoy combo for kidney cancer pharmatimes
December 11, 2018
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
NICE u-turn on Opdivo for skin cancer recurrence pharmatimes
November 30, 2018
NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence...
Azacitidine and nivolumab combo proves successful in phase II trial pharmatimes
November 14, 2018
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or refractory
Shares in Mirati plummet after disappointing Phase II trial pharmafile
November 01, 2018
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II study of the experimental drug sitravatinib...
Nivolumab reduces size of some lung cancer tumours, relapse rate after surgery europeanpharmaceuticalreview
April 17, 2018
A drug given to early-stage lung cancer patients before they undergo surgery showed major tumour responses in the removed tumour…

Previous page 1 2 3 Next page